Global Immunotherapy Drugs Market is Segmented By Drug Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins Checkpoint Inhibitors, Other), By Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, Others), By Distribution Channel (Hospitals, Clinics, Cancer Research Center, Other), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Immunotherapy Drugs Market Overview
The Global Immunotherapy Drugs Market is estimated to reach at a CAGR of 10.1% during the forecast period (2024-2031).
Immunotherapy is a treatment that uses a person's immune system to fight cancer. Immunotherapy can boost or change how the immune system works so it can find and attack cancer cells. Immunotherapy drugs are used to enhance or suppress the immune system of the body. They are mostly used in the treatment of cancer and act by stimulating the immune system of the body and generating an immune response aiding the production of antibodies.
Immunotherapy Drugs Market Summary
|
Metrics |
Details |
|
Market CAGR |
10.1% |
|
Segments Covered |
By Drug Type, By Therapy Area, By Distribution Channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
For More Insights Request Free Sample
Immunotherapy Drugs Market Dynamics
The global immunotherapy drugs market growth is driven by the increasing adoption of targeted therapies, increase in the life span of patients, and high prevalence of lifestyle diseases.
The global immunotherapy drugs market is driven by the rising incidences of cancer
The major factor for most cancers is the rise in the geriatric population, as cancer rates increase with age. According to a report from WHO in 2015, approximately 50% of people treated with cancer in the U.K. are over the age of 60. Obesity, change in lifestyle, smoking, and eating habits are other important factors that are increasing the number of cancer patients. People are favoring cancer treatments with lesser side effects. This factor is likely to drive the growth of the global immunotherapy drugs market in the forecast period, as immunotherapy drugs are found to have lesser side effects as compared to other treatments. The rise in opportunities in developing markets and immunotherapy as a substitute to chemotherapy for first-line treatment are drivers which are expected to drive the growth of the market. In addition, a quicker drug approval process and a high prevalence rate of lifestyle diseases are projected to drive market growth during the forecast period.
The rising adoption of targeted therapy over traditional therapy will drive the market
The major factors attributing to the growth of the immunotherapy drugs market are the rising adoption of targeted therapy over traditional therapy, emergence of biosimilars. Furthermore, immunotherapy drugs are widely used in cancer treatment.
For instance, over the past decade, there has been a continuous rise in the prevalence of several chronic diseases, which, in several cases, need immune therapies. Some of the major chronic diseases include cancer, kidney failure, and heart diseases. Several lifestyle disorders, both chronic and non-communicable diseases, such as hypertension, diabetes, obesity, and depression, need critical care during hospitalization. Thus, the rise in the number of diseases and associated disorders is among the major primary reasons for the growth of this immunotherapy drugs market.
Risks associated with use is likely to hinder the market growth
However, for patients receiving immunotherapy drugs that are given intravenously, the most common side effects include skin reactions at the site of the injection, such as pain, swelling, and soreness. Some immunotherapy drugs may cause severe or even fatal allergic reactions, though this is rare. This factor is hampering the growth of the market.
COVID-19 Impact on Immunotherapy Drugs Market
The havoc caused by the COVID-19 pandemic continues to disrupt daily life, but its reach goes deeper and further with mounting consequences for cancer patients who need ongoing treatment. Hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease, forcing cancer patients to weigh the potential benefit of a face-to-face visit and treatment with the risks of catching the virus. The COVID-19 pandemic has impacted virtually every aspect of cancer care and research from introducing new risks for cancer patients to disrupting the delivery of cancer treatment and the continuity of cancer research, a review of scientific literature shows. This factor will hamper the growth of the immunotherapy drugs market.
Immunotherapy Drugs Market Segmentation Analysis
The monoclonal antibodies segment is expected to grow at the fastest CAGR during the forecast period (2024-2031)
Monoclonal antibodies (mAbs), a type of mono-specific antibodies, are comprised of identical antibody molecules and are produced by a single clone of cells or cell lines. Monoclonal antibodies have brought about a fundamental change in the pharmaceutical and biotechnology sectors and in the future too are slated to play a crucial role in clinical protocol with further development of these molecular agents. Monoclonal antibodies find application in the treatment of a variety of diseases, particularly autoimmune, cancer, and inflammatory diseases. Increasing R&D pertaining to the development of therapeutic mAbs coupled with supportive government initiatives is expected to drive the monoclonal antibodies segment growth over the forecast period.
Additionally, the increasing drug approvals and launches of novel monoclonal antibodies for various diseases treatments such as cancer, robust research, and development of monoclonal antibodies for multiple diseases and technologies such as the advent of mammalian cell culture, process, and formulation technology is expected to be significant market opportunities.
Cancer is expected to dominate the immunotherapy drugs market during the forecast period
Cancer is an abnormal growth of the cells in the body. There are more than 100 different types of cancer. According to the World Cancer Research Fund, in 2018, there were an estimated 18 million cancer cases around the world, out of which, 9.5 million cases were in men and 8.5 million in women. This cancer prevalence is expected to be the same in the coming years, which is helping the market to grow. There are several types of immunotherapies used for the treatment of cancer. Some of the immunotherapies include immune checkpoint inhibitors, T-cells cell transfer, cancer vaccines, and immune system modulators. In 2005, 7.6 million people died of cancer out of 58 million deaths worldwide. Based on projections, cancer deaths will continue to rise with an estimated 9 million people dying from cancer in 2015, and 11.4 million dying in 2030. The increasing trend of cancer incidence has forced humanity to work more on cancer prevention and treatments.
According to a report from WHO in 2015, approximately 50% of people treated with cancer in the U.K. are over the age of 60. Obesity, change in lifestyle, smoking, and eating habits are other important factors that are increasing the number of cancer patients. People are favoring cancer treatments with lesser side effects. This factor is likely to drive the growth of the segment.
Solid Tumor: Solid tumors include cancers of the brain, ovary, breast, colon, and other tissues. These cancer stem cells are thought to divide to produce the bulk of the cells that make up the tumor. In 2005, 7.6 million people died of cancer out of 58 million deaths worldwide. More than 70% of all cancer deaths occur in low and middle-income countries, where resources available for the prevention, diagnosis, and treatment of cancer are limited or nonexistent. Based on projections, cancer deaths will continue to rise with an estimated 9 million people dying from cancer in 2015, and 11.4 million dying in 2030.
Malignant: Malignant refers to cancer cells that can invade and kill nearby tissue and spread to other parts of the body. Cancer is any form of cancer or growth that can spread to other parts of the body in a process called metastasis. It is compared to benign growths or cancers that do not easily spread to other parts of the body and maybe much easier to treat. Malignant can be defined as progressive, bad, and resistant to any form of treatment, but it shouldn’t be understood as necessarily fatal. Caught early, many forms of cancer can be treated through the removal of tumors and additional measures like chemotherapy and radiation.
Immunotherapy Drugs Market Geographical Share
North America region holds the largest market share global immunotherapy drugs market
North America region is dominating the global immunotherapy drugs market accounted for the largest market share in 2020, owing to the increasing incidence of cancers, rising geriatric population, growing preference, and adoption rate of immunotherapy rates across the region.
According to the estimates of the American Cancer Society, in 2018, there would be 1,735,350 new cancer cases diagnosed and 609,640 deaths, due to cancer in the United States. The most common cancers in the United States are breast cancer, lung cancer, prostate cancer, colorectum cancer, bladder cancer, and skin cancer.
In the North American region, the United States holds the largest market share. Factors, such as increased awareness among people for the early detection of diseases, better reimbursement policies, healthcare expenditure with better infrastructure, and rising prevalence of chronic and lifestyle disorders are the primary factors propelling the immunotherapy drugs market in the United States.
Immunotherapy Drugs Companies and Competitive Landscape
The immunotherapy drugs market is moderately competitive with the presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include F. Hoffmann-La Roche AG, GlaxoSmithKline plc. AbbVie, Inc., Amgen, Inc., Merck & Co., Inc., Alligator Bioscience, UbiVac, Bristol-Myers Squibb, Novartis International AG, and AstraZeneca plc, Daiichi Sankyo Company. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the immunotherapy drugs market globally.
Key Companies to Watch
Daiichi Sankyo Company
Overview: Daiichi Sankyo Company, Limited researches and develops manufactures, imports, and markets pharmaceutical products worldwide. Founded on September 28, 2005, through the merger of Daiichi Pharmaceutical and Sankyo. The Group manufactures pharmaceuticals for human/veterinary use and medical tools and equipment. It also researches and promotes products through related companies throughout the world. The Group also produces food, food additives, livestock feeds, and agrochemicals.
Product Portfolio: The Company’s portfolio comprised of prasugrel, an antiplatelet agent, denosumab for osteoporosis and bone compilations; teneligliptin for type 2 diabetes mellitus treatment; edoxaban, an anticoagulant; esomeprazole for ulcer treatment; memantine and donepezil for treating Alzheimer's disease; laninamivir for anti-influenza treatment; and silodosin for treating dysuria. It also provides olmesartan and Telmisartan antihypertensive agents; levofloxacin, an antibacterial agent; pravastatin and Rosuvastatin antihyperlipidemic agents; iohexol to enhance the visibility of diagnostic X-ray imaging; loxoprofen, an anti-inflammatory analgesic; and naloxegol for opioid-induced constipation treatment.
Key Development: On August 2, 2019, Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) approved TURALIO™ (pexidartinib) as the first and only treatment for adult patients with symptomatic TGCT associated with severe morbidity or functional limitations and not amenable to improvement with surgery. TGCT is a rare, non-malignant tumor that affects small and large joints.
